Detailed Narrative
High-Value Solutions & GLP-1 Momentum
High-Value Solutions (HVS) were a primary driver of revenue growth and margin expansion in FY25, increasing 29% and representing 46% of total revenue. GLP-1 related revenue grew over 50% in FY25, accounting for 19-20% of total revenue, and is expected to grow mid-teens in FY26. The Nexa syringe is a key product for GLP-1s, and the company is expanding capacity for both syringes and cartridges to meet demand, anticipating GLP-1s to remain a significant tailwind.
Strategic Shift and Biologics Focus
Stevanato is pivoting away from non-high-value product categories, focusing investments on biologic applications. Biologics represented 41% of BDS revenues in FY25, up from 34% in FY24. The company saw a 40% increase in customers ordering premium syringes (Alba and Nexa) for non-GLP-1 biologic applications, indicating broader market penetration. This strategy aims to position Stevanato as a leading partner for injectable biologics and biosimilars.
Capacity Expansion and Operational Ramp-up
Significant investments are ongoing in Latina, Italy, and Fishers, Indiana, to expand capacity for high-value syringes and EZ-fill cartridges. Latina is nearing average gross profit margin, while Fishers, a more complex plant, is showing steady improvement but will take longer to reach full run-rate profitability. Customer validations and audits have doubled in Fishers in FY25, with line installations continuing throughout 2026.
Engineering Segment Optimization
The Engineering Segment underwent rightsizing, streamlined processes, and reinforced its project management office in FY25, leading to double-digit growth in site-acceptance rates. Despite these operational improvements, the segment's revenue declined 23% in Q4 FY25 and is guided to decline mid-single to low double digits in FY26 due to slower order intake, though the opportunity pipeline is robust, particularly in pharmaceutical visual inspection.
Contract Manufacturing Activities
The company is advancing the build-out for contract manufacturing in support of large device programs for a key U.S. customer, with commercial activities expected to begin in late 2026 or early 2027. Nearly all injection molding machines are installed, and components are being produced for qualification activities. This selective approach leverages integration between syringes, auto-injectors, and other capabilities.
GLP-1 Market Evolution
Management expects the GLP-1 market to evolve over the next decade, driven by originator strategies, biosimilar launches, expanded treatment indications, and next-generation incretins. While oral GLPs expand the market, injectables are expected to remain the preferred format for obesity treatments, with the company estimating injectables will represent approximately 70% of the market, without significant cannibalization of existing injectable demand.
U.S. Onshoring and Supply Chain
The Fishers plant is strategically positioned to serve U.S. supply chain needs, mirroring European capabilities for EZ-Fill technology and devices. This presence is accelerating opportunities for customers seeking a domestic U.S. supply chain, leveraging the plant's wide capabilities for syringes, vials, and drug delivery systems.